There is, therefore, an exciting prospect to combine strategies that target iNOS expression in MDSCs together with existing immunotherapies such as immune checkpoint inhibitors in cancer treatment to achieve enhanced anti-tumour effects. Here, NOS2 is linked to neoplasm.